Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 52

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 52
---
 approval, we effected a one-for-20 reverse split of our ordinary shares, and our ordinary shares began trading on AIM on a
split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock split.

Concurrently with the reverse
split, and in an effort to bring the Depositary Shares price into compliance with NASDAQ’s minimum requirement for 500,000 listed
Depositary Shares, on March 27, 2023, we effected a ratio change in the number of our ordinary shares represented by the Depositary Shares
from 25 ordinary shares per Depositary Share to five ordinary shares per Depositary Share. No fractional Depositary Shares were issued.

Between March 27, 2023 and
December 31, 2024, we have issued 95,137,075 Ordinary Shares upon the exercise of pre-funded warrants, Series A Warrants and Series B
Warrants issued in the February Private Placement.

On May 26, 2023, we completed
the closing of the a registered direct offering with institutional investors of (1) 166,017,700 Ordinary Shares represented by 16,601
Depositary Shares, issuable upon the exercise of the Series C warrants, or Series C Warrants, at an exercise price of $400.00 per warrant,
(2) 110,675,600 Ordinary Shares represented by 11,059 Depositary Shares issuable upon the exercise of the Series D warrants, or Series
D Warrants, at an exercise price of $400.00 per warrant and, (3) 4,426,800 Ordinary Shares represented by 442 Depositary Shares issuable
upon the exercise of warrants issued to the placement agent in the offering at an exercise price of $375.00 per warrant, or May 2023 Placement
Agent Warrants.

On June 14, 2023, we held
our June AGM, and our shareholders passed resolutions, among other procedural items, to approve the allotment of, and disapplication of
pre-emption rights in respect of, up to 7.0 billion Ordinary Shares. On June 14, 2023, we also held a June GM, and our shareholders passed
resolutions to, among other things, (i) re-designate our deferred shares into A Deferred Shares, and (ii) subdivide our Ordinary Shares
of £0.02 nominal value each into one Ordinary Share of £0.001 nominal value and 19 B